Reply Authors: Hendrik B Sager Published: 2026 Myocardial infarction (MI) induces a strong systemic inflammatory response. Although the initial inflammatory response, including the recruitment of inflammatory leukocytes from the circulation and the local production of cytokines and chemokines, is essential for the clearance of necrotic tissue and the initiation of tissue repair, excessive or prolonged inflammation can be detrimental. According to our recent findings, persistent inflammation, as evidenced by elevated blood leukocyte counts on day 3 after MI, may contribute to infarct expansion, adverse cardiac remodeling, and increased mortality.1 How can these findings be translated into improved treatment strategies for patients with MI? Specifically, how can we lower the supply of inflammatory cells during MI? In this context, we appreciate the letter by Del Buono et al2, who have spearheaded some of the first clinical trials investigating anti-inflammatory therapies in acute MI. Their work was among the first to demonstrate the druggability of the interleukin-1β/interleukin-6/C-reactive protein axis. Targeting interleukin-1β effectively reduces circulating leukocyte levels after MI in mice,3 with similar anti-inflammatory effects previously demonstrated in patients with progressive atherosclerosis.4 Likewise, treatment with anakinra, an interleukin-1 receptor antagonist, resulted in a marked reduction in postinfarction leukocyte counts compared with placebo. Importantly, patients in whom leukocyte levels failed to decline (“nonresponders”) experienced a higher rate of adverse clinical outcomes.2 In addition to serving as a biomarker for treatment response, as elegantly demonstrated by Del Buono et al2, our results may also help identify patients who are most likely to benefit from anti-inflammatory therapy and guide the optimal timing of treatment initiation. Rather than administering anti-inflammatory therapy to all patients with MI immediately after MI, thereby potentially interfering with the essential early inflammatory response, a more personalized approach may be warranted. Patients with persistent or excessive inflammation, who remain at increased risk of adverse cardiac remodeling, may benefit more from delayed initiation of anti-inflammatory therapy after the initial inflammatory burst has subsided. Together, these findings support a more nuanced approach to anti-inflammatory therapy after MI. Unlike C-reactive protein, a downstream biomarker of inflammation, circulating leukocytes are key effector cells of the innate immune response and directly contribute to myocardial injury and repair. Accordingly, leukocyte kinetics after MI may help identify patients with persistent inflammatory activation, monitor treatment response, and guide the initiation of anti-inflammatory therapy. Tailoring treatment to patients with sustained inflammation may maximize therapeutic benefit while preserving the early inflammatory response required for effective infarct healing. Footnotes Dr Sager has received lecture fees and travel support from Novo Nordisk Pharma GmbH, AstraZeneca GmbH, Translumina, and Abbott Medical GmbH (unrelated to this work). The author attests they are in compliance with human studies committees and animal welfare regulations of the author’s institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References